Madeline Molman

Analyst

Wolfe Research

Equibles does not estimate personal net worth.

About Madeline Molman

Madeline Molman is recorded as Analyst at Wolfe Research. Madeline Molman has spoken on 4 earnings calls across 3 companies, most recently for 10x Genomics, Inc. on May 7, 2026. Those appearances were for 10x Genomics, Inc. (TXG), Repligen Corp (RGEN) and Bruker Corp (BRKR). The companies whose calls Madeline Molman spoke on are classified in the Healthcare sector.

Madeline Molman on recent calls

“Growth margin in the quarter I think came in a little better than we in the street were expecting. As we think about the full year, are you anticipating any impact to growth margin from increased inflationary pressures related to memory or petroleum-based plastics?”

Analyst — Wolfe Research, 10x Genomics, Inc. Q1 FY2026 Earnings Call · May 7, 2026

“You mentioned that there was a pickup in equipment in March. Where was the strength most notable? Was it by category and customer type? And did that help you in the quarter or was it more the order book?”

Analyst — Wolfe Research, Repligen Corp Q1 FY2026 Earnings Call · May 5, 2026

“The guide calls for a 5% sequential pickup, can you walk through how much of that is expected to come from instruments versus consumables, especially given you're not assuming a year-end budget flush?”

Analyst — Wolfe Research, 10x Genomics, Inc. Q3 FY2025 Earnings Call · November 6, 2025

“For Gerald, if conditions with the NIH or in China do deteriorate, can you talk through what levers you have at your disposal to protect the margin and EPS guidance?”

Analyst — Wolfe Research, Bruker Corp Q4 FY2024 Earnings Call · February 13, 2025